Has Arthur Kornbluth received payments from drug or device companies?

Yes. Drug and device makers reported $1,885,717 in general payments to Arthur Kornbluth across 2,650 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Arthur Kornbluth did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Arthur Kornbluth come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Arthur Kornbluth

Gastroenterology · New York, NYNPI 1104835784

Payments from drug & device makers

$1,885,717in general payments, 2019–2025

Across 2,650 payments — averaging $711.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$447K
E.r. Squibb & Sons, L.L.C.$309K
Johnson & Johnson$281K
Janssen Scientific Affairs, LLC$262K
Pfizer$228K
Takeda Pharmaceuticals U.S.A., Inc.$116K
plus $242K from 31 others

What the payments were for

Consulting fees$143,4588%
Speaking & faculty fees$1,530,21881%
Travel & lodging$159,2068%
Food & beverage$52,5843%
Education$2510%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	603	$447,312
E.r. Squibb & Sons, L.L.C.	187	$308,637
Johnson & Johnson	311	$281,262
Janssen Scientific Affairs, LLC	235	$262,297
Pfizer	256	$227,809
Takeda Pharmaceuticals U.S.A., Inc.	202	$116,148
Lilly USA, LLC	96	$104,664
Celltrion USA Inc.	33	$67,760
Amgen	27	$40,810
Bristol Myers Squibb	306	$11,266
Merck	34	$11,243
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	166	$2,371
QOL Medical, LLC	32	$758
Gilead	1	$640
UCB, Inc.	36	$438
Ferring Pharmaceuticals Inc.	24	$300
Daiichi Sankyo Inc.	14	$287
Boehringer Ingelheim	7	$202
Organon	8	$167
Ironwood Pharmaceuticals, Inc	7	$155
Shire North American Group Inc	12	$138
Regeneron Healthcare Solutions, Inc.	5	$126
Phathom Pharmaceuticals, Inc.	10	$120
Exact Sciences	6	$116
Endo Pharmaceuticals Inc.	5	$103
Ardelyx, Inc.	4	$97
Sandoz	3	$94
Nestle Healthcare Nutrition Inc.	4	$72
Aimmune Therapeutics, Inc.	3	$52
Braintree Laboratories, Inc.	2	$48
Vivus LLC	2	$44
Boston Scientific	2	$43
Romark Laboratories, LC	2	$42
GSK	2	$34
Fresenius Kabi USA, LLC	1	$22
Novo Nordisk	1	$21
Redhill Biopharma Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

STELARA$431,815
ZEPOSIA$304,017
Tremfya$193,228
Skyrizi$159,808
XELJANZ$142,539
Humira$126,648
Rinvoq$122,514
Entyvio$113,356
OMVOH$93,705
VELSIPITY$73,878
ZYMFENTRA$67,268
AVSOLA$40,500
RENFLEXIS$8,030
INFLECTRA$3,250
VEGZELMA$344

How this compares

$1,885,717 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
StelaraUstekinumab	17	$489,542
Humira(Cf) PenAdalimumab	13	$88,550
XifaxanRifaximin	12	$33,781
Mesalamine	25	$18,524
Omeprazole	26	$286
Pantoprazole Sodium	12	$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonStelara	$281,262	$489,54217 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan	$2,371	$33,78112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

David HudesmanNew York$3.6M
Ellen ScherlNew York$2.9M
Bruce SandsNew York$2.8M
Arun SwaminathNew York$2.7M
Sonal KumarNew York$2.3M
David Carr LockeNew York$2.1M
Ira JacobsonNew York$1.8M
James MarionNew York$1.7M
Jean Frederick ColombelNew York$1.6M
Scott FriedmanNew York$1.5M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →